CR20210376A - COMPUESTOS Y USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA - Google Patents

COMPUESTOS Y USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA

Info

Publication number
CR20210376A
CR20210376A CR20210376A CR20210376A CR20210376A CR 20210376 A CR20210376 A CR 20210376A CR 20210376 A CR20210376 A CR 20210376A CR 20210376 A CR20210376 A CR 20210376A CR 20210376 A CR20210376 A CR 20210376A
Authority
CR
Costa Rica
Prior art keywords
treatment
antitrypsin deficiency
compounds
derivatives
a1ad
Prior art date
Application number
CR20210376A
Other languages
English (en)
Inventor
James Andrew Huntington
David John Fox
Nigel Ramsden
Original Assignee
Z Factor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Z Factor Ltd filed Critical Z Factor Ltd
Publication of CR20210376A publication Critical patent/CR20210376A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a derivados de oxopirimidinil-metil-benzamida, por ejemplo en forma de una sal o cristal farmacéuticamente aceptable, composiciones farmacéuticas que comprenden los derivados y a su uso médico, en particular para su uso en el tratamiento de la deficiencia de α1-antitripsina (A1AD o AATD)
CR20210376A 2018-12-14 2019-12-13 COMPUESTOS Y USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA CR20210376A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1820450.3A GB201820450D0 (en) 2018-12-14 2018-12-14 Compound and its use for the treatment of alpha1-antitryspin deficiency
PCT/GB2019/053552 WO2020120992A1 (en) 2018-12-14 2019-12-13 COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Publications (1)

Publication Number Publication Date
CR20210376A true CR20210376A (es) 2021-10-18

Family

ID=65147137

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210376A CR20210376A (es) 2018-12-14 2019-12-13 COMPUESTOS Y USO PARA EL TRATAMIENTO DE LA DEFICIENCIA DE a1-ANTITRIPSINA

Country Status (22)

Country Link
US (2) US11312689B2 (es)
EP (1) EP3894393B8 (es)
JP (1) JP7487203B2 (es)
KR (1) KR20210104080A (es)
CN (1) CN113227057B (es)
AU (1) AU2019398520B2 (es)
BR (1) BR112021011477A2 (es)
CA (1) CA3122658A1 (es)
CO (1) CO2021009083A2 (es)
CR (1) CR20210376A (es)
EA (1) EA202191239A1 (es)
EC (1) ECSP21051825A (es)
GB (1) GB201820450D0 (es)
IL (1) IL283938B2 (es)
MA (1) MA54456A (es)
MX (1) MX2021006884A (es)
NI (1) NI202100047A (es)
PE (1) PE20211789A1 (es)
PH (1) PH12021551302A1 (es)
SG (1) SG11202105878WA (es)
WO (1) WO2020120992A1 (es)
ZA (1) ZA202103977B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
GB201918414D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB201918404D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB202009074D0 (en) 2020-06-15 2020-07-29 Z Factor Ltd Compound
GB202009069D0 (en) * 2020-06-15 2020-07-29 Z Factor Ltd Process
GB202108544D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108542D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108543D0 (en) * 2021-06-15 2021-07-28 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
WO2022263829A1 (en) * 2021-06-16 2022-12-22 Z Factor Limited COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3719100A (en) * 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
EP1250129A2 (en) * 2000-01-20 2002-10-23 Washington University METHODS TO TREAT $g(a)-1-ANTITRYPSIN DEFICIENCY
US20070167621A1 (en) * 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
US7183287B2 (en) * 2003-04-03 2007-02-27 Pharmacia Corporation Substituted pyrimidinones
EP1735319B1 (en) * 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
US7253204B2 (en) 2004-03-26 2007-08-07 Methylgene Inc. Inhibitors of histone deacetylase
GB0604613D0 (en) 2006-03-07 2006-04-19 Simpson Brian A Electrostimulation device
EP1832586A1 (en) * 2006-03-10 2007-09-12 Oridis Biomed Forschungs- und Entwicklungs GmbH Thiazole-piperidine derivatives in treatment of diseases of liver and the pancreas
EP2114141A2 (en) * 2007-01-10 2009-11-11 University of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
CN101224207A (zh) * 2007-10-12 2008-07-23 中国科学院上海有机化学研究所 具有诱导自吞噬治疗错误折叠蛋白聚集所致疾病的药物及其筛选方法
RS52270B (sr) * 2007-12-20 2012-10-31 Bayer Pharma Aktiengesellschaft 4-(4-cijano-2-tioaril)-dihidropirimidinon i njegova primena
PH12014500888A1 (en) * 2011-11-08 2014-06-09 Arena Pharm Inc Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto
CA2855211A1 (en) * 2011-11-11 2013-05-16 Pfizer Inc. N-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide for the treatment of chronic myelogenous leukemia
KR101781922B1 (ko) 2012-04-10 2017-09-26 안지 파마슈티컬 코퍼레이션 리미티드 히스톤 탈아세틸효소(hdacs) 억제제
US20140221335A1 (en) * 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
JP6632532B2 (ja) * 2014-08-29 2020-01-22 国立大学法人 東京大学 オートタキシン阻害活性を有するピリミジノン誘導体
IL279526B2 (en) 2018-06-22 2026-05-01 Ucl Business Ltd Compounds for the treatment of alpha-1 antitrypsin-mediated diseases
AU2019362753A1 (en) 2018-10-05 2021-05-20 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
GB201820450D0 (en) 2018-12-14 2019-01-30 Z Factor Ltd Compound and its use for the treatment of alpha1-antitryspin deficiency
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
GB201918413D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB201918404D0 (en) 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of aplha1-antitrypsin deficiency
GB201918414D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
GB202009069D0 (en) * 2020-06-15 2020-07-29 Z Factor Ltd Process
GB2612007A (en) * 2021-06-15 2023-04-26 Z Factor Ltd Compounds
WO2022263829A1 (en) * 2021-06-16 2022-12-22 Z Factor Limited COMPOUNDS AND THEIR USE FOR THE TREATMENT OF α1-ANTITRYPSIN DEFICIENCY

Also Published As

Publication number Publication date
SG11202105878WA (en) 2021-07-29
US12221422B2 (en) 2025-02-11
AU2019398520B2 (en) 2025-07-03
CN113227057A (zh) 2021-08-06
MA54456A (fr) 2022-03-23
PH12021551302A1 (en) 2022-03-28
AU2019398520A1 (en) 2021-07-01
JP7487203B2 (ja) 2024-05-20
US20210332015A1 (en) 2021-10-28
IL283938A (en) 2021-07-29
PE20211789A1 (es) 2021-09-09
EP3894393B1 (en) 2022-12-21
EP3894393A1 (en) 2021-10-20
WO2020120992A1 (en) 2020-06-18
GB201820450D0 (en) 2019-01-30
MX2021006884A (es) 2021-09-14
US20220274932A1 (en) 2022-09-01
IL283938B2 (en) 2026-03-01
CA3122658A1 (en) 2020-06-18
US11312689B2 (en) 2022-04-26
CO2021009083A2 (es) 2021-07-30
CN113227057B (zh) 2025-02-25
EA202191239A1 (ru) 2021-09-21
EP3894393B8 (en) 2023-02-15
BR112021011477A2 (pt) 2021-08-31
IL283938B1 (en) 2025-11-01
ZA202103977B (en) 2022-10-26
JP2022515372A (ja) 2022-02-18
NI202100047A (es) 2021-08-31
ECSP21051825A (es) 2021-11-18
KR20210104080A (ko) 2021-08-24

Similar Documents

Publication Publication Date Title
PH12021551302A1 (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EP4684836A3 (en) Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
MY190835A (en) Bicyclic heterrocyclic derivatives as bromodomain inhibitors
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
PH12016502352A1 (en) Pharmaceutical composition
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
PL424452A1 (pl) Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
PH12017501668A1 (en) Bace1 inhibitors
MY208388A (en) Vaginal tablet formulation
MX2019014773A (es) Inhibidores de ccl2.
NZ780408A (en) Human plasma kallikrein inhibitors
EA201791798A1 (ru) Фармацевтические композиции, включающие n-(3,5-диметоксифенил)-n'-(1-метилэтил)-n-[3-(1-метил-1h-пиразол-4-ил)хиноксалин-6-ил]этан-1,2-диамин